No cure in sight for the world's drug problem.
No cure in sight for the world's drug problem.
复制标题
DOI：
10.1016/s1470-2045(09)70131-7
复制
发表时间：
2009-05
期刊：
影响因子：
--
通讯作者：
David R. Holmes
中科院分区：
文献类型：
--
作者：
David R. Holmes
如果您是一名ERBB2阳性晚期乳腺癌患者，且对治疗无效，拉帕替尼治疗可以让您有机会控制疾病。除非你是英国国民健康服务（NHS）的病人。因为在2009年3月4日，英国国家临床卓越研究所（NICE）裁定，NHS不应该处方拉帕替尼治疗，因为它是“不符合成本效益的使用NHS资源”。当然，英国不是唯一一个无法负担拉帕替尼治疗的国家，但到目前为止，16个欧洲邻国已经批准了资金批准，包括斯洛文尼亚，斯洛伐克，法国，西班牙，德国、意大利和爱尔兰。
If you are a woman with ERBB2-positive advanced breast cancer that has failed to respond to therapy, lapatinib treatment could give you the chance to control your disease. Unless, that is, you are a patient of the UK National Health Service (NHS). Because on March 4, 2009, the UK National Institute of Clinical Excellence (NICE) ruled that the NHS should not prescribe lapatinib treatment as it is “not a cost-effective use of NHS resources”.Of course the UK is not the only country that cannot afford to prescribe lapatinib treatment, but so far 16 of its European neighbours have granted funding approval, including Slovenia, Slovakia, France, Spain, Germany, Italy and Ireland.